Parkinson’s Disease Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

List of Contents

List of Tables

List of Figures

1 Parkinson’s Disease: Executive Summary

1.1 Summary of Changes

1.2 The PD market will grow to $7.0 billion

1.3 Novel symptomatic treatments will continue to shape the PD market

1.4 Opportunities and challenges for disease-modifying therapies entering the PD market

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming related reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of PD

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of PD by HY clinical staging

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PD by inheritance type

4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of PD by motor complications

4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PD by neuropsychiatric complications

4.5 Epidemiological forecast for PD (2023–33)

4.5.1 Diagnosed prevalent cases of PD

4.5.2 Age-specific diagnosed prevalent cases of PD

4.5.3 Sex-specific diagnosed prevalent cases of PD

4.5.4 Diagnosed prevalent cases of PD by HY clinical staging

4.5.5 Diagnosed prevalent cases of PD by type

4.5.6 Diagnosed prevalent cases of PD by inheritance type

4.5.7 Diagnosed prevalent cases of PD by motor complications

4.5.8 Diagnosed prevalent cases of PD by neuropsychiatric complications

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Effective treatment of motor complications – dyskinesia, off episodes, gait, and balance problems

7.3 New therapies for non-motor complications – psychosis and dementia

7.4 Neuroprotective or disease-modifying agents

7.5 Formulations that reduce pill burden

8 R&D Strategies

8.1 Overview

8.1.1 Development of novel targets ─ targeting cell and gene therapies and α-synuclein

8.1.2 Innovative drug delivery systems

8.1.3 Secondary indications, post marketing requirements, and drug repurposing

8.2 Clinical trials design

8.2.1 Reliable biomarkers of disease progression

8.2.2 Genetic studies required to learn about genetic subtypes of PD

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

10.2.1 Levodopa therapies

10.2.2 Dopamine agonists/combinations

10.2.3 Antiparkinsonian agents targeting motor complications

10.2.4 Assets targeting PD dementia

10.2.5 Neuroprotective and disease-modifying agents

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.5 Primary research – prescriber survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologists

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us

Table 1: Parkinson’s disease: key metrics in the 7MM

Table 2: Summary of changes to Parkinson’s Disease: Seven-Market Drug Forecast and Analysis report

Table 3: Modified HY scale of PD symptoms

Table 4: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2019

Table 5: Risk factors and comorbidities of PD

Table 6: Treatment guidelines for PD

Table 7: Top 10 deals by value, 2014–25

Table 8: PD market – global drivers and barriers, 2023–33

Table 9: Key events impacting sales for PD in the US, 2023–33

Table 10: PD market – drivers and barriers in the US, 2023–33

Table 11: Key events impacting sales for PD in the 5EU, 2023–33

Table 12: PD market – drivers and barriers in the US, 2023–33

Table 13: Key events impacting sales for PD in Japan, 2023 and 2033

Table 14: PD market – drivers and barriers in Japan, 2023–33

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for Parkinson’s disease in 2023 and 2033

Figure 2: Analysis of the company portfolio gap in PD during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that are investigated for disease-modifying/neuroprotective properties that GlobalData expects to be licensed for the treatment of PD during the forecast period

Figure 4: 7MM, diagnosed prevalence of PD, both sexes, ages ≥18 years, %, 2023

Figure 5: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PD

Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by HY clinical staging

Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by inheritance type

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by motor complications

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by neuropsychiatric complications

Figure 10: 7MM, diagnosed prevalent cases of PD, N, both sexes, ages ≥18 years, 2023

Figure 11: 7MM, age-specific diagnosed prevalent cases of PD, N, both sexes, 2023

Figure 12: 7MM, sex-specific diagnosed prevalent cases of PD, N, ages ≥18 years, 2023

Figure 13: 7MM, diagnosed prevalent cases of PD by HY clinical staging, both sexes, ages ≥18 years, N, 2023

Figure 14: 7MM, diagnosed prevalent cases of PD by type, both sexes, ages ≥18 years, N, 2023

Figure 15: 7MM, diagnosed prevalent cases of PD by inheritance type, both sexes, ages ≥18 years, N, 2023

Figure 16: 7MM, diagnosed prevalent cases of PD by motor complications, N, both sexes, ages ≥18 years, 2023

Figure 17: 7MM, diagnosed prevalent cases of PD by neuropsychiatric complications, N, both sexes, 2023

Figure 18: Treatment algorithm for PD patients: Treatment of Motor Complications

Figure 19: Unmet needs and opportunities in PD

Figure 20: Overview of PD pipeline in the 7MM

Figure 21: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PD in the 7MM during the forecast period

Figure 22: Competitive assessment of the pipeline levodopa therapies benchmarked against the SOC, Sinemet

Figure 23: Competitive assessment of the pipeline dopamine agonist drugs benchmarked against the SOC, Requip XL

Figure 24: Competitive assessment of the pipeline antiparkinsonian drugs benchmarked against the SOC, Gocovri

Figure 25: Competitive assessment of PD dementia agents benchmarked against the SOC, Exelon

Figure 26: Competitive assessment of the pipeline neuroprotective/DMT drugs benchmarked against the SOC, Azilect

Figure 27: Analysis of the company portfolio gap in PD during the forecast period

Figure 28: Global (7MM) sales forecast by country for PD in 2023 and 2033

Figure 29: Sales forecast by class for PD in the US in 2023 and 2033

Figure 30: Sales forecast by class for PD in the 5EU in 2023 and 2033

Figure 31: Sales forecast by class for PD in Japan in 2023 and 2033